| |
| |
|
| Insider
Information: |
Moran Susan |
| Relationship: |
|
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
12,307 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
12,307 |
|
|
| Total
Value |
$0 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Bioatla, Inc. |
BCAB |
Director |
2020-12-15 |
12,307 |
|
0 |
Premium* |
|
|
Rayzebio, Inc. |
RYZB |
|
2024-02-26 |
0 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
4 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RYZB |
Rayzebio, Inc. |
CHIEF MEDICAL OFFICER |
• – – |
2024-02-26 |
4 |
D |
$62.50 |
$20,215,938 |
D/D |
(323,455) |
0 |
0 |
- |
|
| RYZB |
Rayzebio, Inc. |
CHIEF MEDICAL OFFICER |
• – – |
2024-01-22 |
4 |
OE |
$3.24 |
$100,035 |
D/D |
30,875 |
322,647 |
0 |
- |
|
| RYZB |
Rayzebio, Inc. |
Chief Medical OfficerOfficer |
• – – |
2023-09-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
291,772 |
|
- |
|
| BCAB |
Bioatla, Inc. |
Director |
– • – |
2020-12-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,307 |
|
- |
|
4 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
